PR Newswire
SAN DIEGO, June 29, 2017
SAN DIEGO, June 29, 2017 /PRNewswire/ -- ResMed (NYSE:
RMD) today announced it will report its fourth quarter of fiscal year 2017 results on Tuesday, August 1,
2017, after the New York Stock Exchange market closes. A press release with ResMed's results will be issued after
1:00 p.m. US Pacific Time and the company will host a webcast to discuss operating results and
future outlook.
The earnings webcast is scheduled to begin at 1:30 p.m. US Pacific Time and the live webcast of
the call can be accessed on ResMed's Investor Relations website at investor.resmed.com. Please go to this section of
the website and click on the icon for the "Q4 2017 earnings webcast."
Please note that we do not use outside phone lines to access the earnings call.
International earnings webcast times will be:
Tuesday, August 1, 9:30 p.m.
|
London
|
Wednesday, August 2, 6:30 a.m.
|
Sydney
|
A replay of the earnings webcast will be accessible on our website and available approximately two hours after the webcast. In
addition, a phone replay will be available approximately two hours after the webcast and will be accessible from August 1, 2017, until August 15, 2017, at:
US:
|
+1 800-585-8367
|
Outside US:
|
+1 416-621-4642
|
Passcode:
|
48372777
|
About ResMed
ResMed (NYSE: RMD) changes lives with award-winning medical devices and cutting-edge cloud-based software applications that
better diagnose, treat and manage sleep apnea, chronic obstructive pulmonary disease (COPD) and other chronic diseases. ResMed is
a global leader in connected care, with more than 3 million patients remotely monitored every day. Our 5,000-strong team is
committed to creating the world's best tech-driven medical device company – improving quality of life, reducing the impact of
chronic disease, and saving healthcare costs in more than 100 countries. ResMed.com | Facebook
| Twitter | LinkedIn.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/resmed-to-announce-fourth-quarter-fiscal-year-2017-results-300482154.html
SOURCE ResMed Inc.